The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Avery Dennison reported adjusted Q3 earnings per share of $2.37, surpassing analyst estimates by $0.05. Similarly, Dexcom announced strong results for the first quarter of 2026, with earnings per share reaching $0.56, beating the consensus estimate of $0.47. According to reports, this positive performance was driven by revenue growth that exceeded expectations for both companies.
Sign in to access this content
Sign InAvery Dennison's growth was fueled by robust demand in the North American market and the increasing adoption of RFID technology, while Dexcom benefited from the widespread uptake of its G7 continuous glucose monitoring system. Compared to healthcare tech peers, Dexcom showed operational resilience similar to Abbott Laboratories, which recently reported strong medical device sales per market data. Avery Dennison's results also reflect stability in the packaging sector, aligning with the performance of peers like Berry Global.
Investors are monitoring the sustainability of profit margins amid fluctuating industrial costs, with a focus on upcoming US industrial production data to gauge sector momentum. Looking at the economic calendar, markets await speeches from Fed officials, including Kashkari on May 7, 2026, for signals on borrowing costs affecting corporate capital expenditure. The outlook for both companies remains positive as innovation continues to drive their respective product pipelines.